(MENAFN - ProactiveInvestors - Australia) Bioniche Life Sciences (ASX: BNC, TSX: BNC) has launched a new product in Canada to treat osteoarthritis in horses.
NexHA„ is a specialised formulation of purified hyaluronate sodium that can be administered to horses by intravenous or intra-articular injection.
The product is indicated in the treatment of joint dysfunction of the carpus or fetlock in horses due to non-infectious synovitis associated with equine osteoarthritis.
Hyaluronate sodium acts as a replacement for synovial fluid, the naturally occurring lubricant in articular joints.
Joint degeneration is associated with the loss of synovial fluid, and the lack of its lubricant effects results in considerable pain and inflammation for the horse.
Lameness due to osteoarthritis is very common in horses.
Bioniche has been developing different formulations of sodium hyaluronate for the equine markets in Canada, Australia and New Zealand " sold as Enhance " since 2001-02.
Both Enhance and NexHA„ are produced with a sodium hyaluronate solution that is obtained from a selective fermentation source using a manufacturing process that is free from thermal degrading effects and delivering high specificity.
Bioniche Animal Health
Bioniche's animal health division is the largest Canada-owned research-based animal health company.
The division has over 60 products sold globally with a focus on reducing reliance on antibiotics (immunology), enhancing reproductive performance and preventing disease (vaccines).
The division reported fiscal 2012 sales of C29.8 million (A28.7 million).